Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Louis Bourgeois

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Microorganisms|April 27, 2024
Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic <i>E. coli</i> Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701)Kawsar R Talaat, Chad K Porter, Subhra Chakraborty, et al.
Vaccine|August 22, 2021
Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coliTida Lee, Ramiro L Gutiérrez, Milton Maciel, et al.
The Journal of Infectious Diseases|March 22, 2019
Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection ModelStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Vaccine|May 9, 2021
Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global accessIbrahim Khalil, Richard Walker, Chad K Porter, et al.
The Journal of Infectious Diseases|May 26, 2017
Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 TrialStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Plos One|December 2, 2020
Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trialKawsar R Talaat, Chad K Porter, Kayla M Jaep, et al.
Clinical Trials (London, England)|October 28, 2021
A site assessment tool for inpatient controlled human infection models for enteric disease pathogensChad K Porter, Katherine J Detizio, Nicole Maier, et al.
Vaccine|September 6, 2005
Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteersB D Kirkpatrick, Robin McKenzie, J Patrick O'Neill, et al.
Ebiomedicine|April 16, 2021
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionKawsar R Talaat, Cristina Alaimo, Patricia Martin, et al.
Ebiomedicine|April 4, 2021
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccineKristen A Clarkson, Kawsar R Talaat, Cristina Alaimo, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Microorganisms|April 27, 2024
Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic <i>E. coli</i> Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701)Kawsar R Talaat, Chad K Porter, Subhra Chakraborty, et al.
Vaccine|August 22, 2021
Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coliTida Lee, Ramiro L Gutiérrez, Milton Maciel, et al.
The Journal of Infectious Diseases|March 22, 2019
Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection ModelStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Vaccine|May 9, 2021
Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global accessIbrahim Khalil, Richard Walker, Chad K Porter, et al.
The Journal of Infectious Diseases|May 26, 2017
Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 TrialStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Plos One|December 2, 2020
Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trialKawsar R Talaat, Chad K Porter, Kayla M Jaep, et al.
Clinical Trials (London, England)|October 28, 2021
A site assessment tool for inpatient controlled human infection models for enteric disease pathogensChad K Porter, Katherine J Detizio, Nicole Maier, et al.
Vaccine|September 6, 2005
Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteersB D Kirkpatrick, Robin McKenzie, J Patrick O'Neill, et al.
Ebiomedicine|April 16, 2021
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionKawsar R Talaat, Cristina Alaimo, Patricia Martin, et al.
Ebiomedicine|April 4, 2021
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccineKristen A Clarkson, Kawsar R Talaat, Cristina Alaimo, et al.
Pageof 7